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Background/aim: Systemic sclerosis (SSc) is an autoimmune disease characterized by microvascular injury, excessive extracellular
matrix deposition, and fibrosis in the skin and internal organs. Bacterial and viral infectious agents have been suspected to be contributing
factors in the development and progression of the pathologic features of SSc.
Materials and methods: In this study, 30 SSc patients who were admitted to the rheumatology unit of the Konya Training and
Research Hospital and 30 healthy controls were included. The presence of 9 different antibodies (IgM and IgG) against Helicobacter
pylori, cytomegalovirus (CMV), Epstein–Barr virus (EBV), and parvovirus B19 were investigated in sera samples obtained from the 60
participants using an enzyme-linked immunosorbent assay method. The characteristics of current and past infections with H. pylori,
CMV, EBV, and parvovirus B19 were evaluated by determining the seropositivity of the tested bacterial and viral agents.
Results: The prevalences of H. pylori, CMV, EBV, and parvovirus B19 were determined to be higher in patients with SSc than in the
control group.
Conclusion: SSc is associated with a higher rate of certain infections, which deserves further investigation in order to assess the role of
infections in disease etiology/pathogenesis.
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1. Introduction
The relationship between infection and autoimmunity has
been increasingly defined in recent years. Bacterial, viral,
and parasitic infections are known to induce and exacerbate
autoimmune diseases (1,2). Systemic sclerosis (SSc) is
an autoimmune disease characterized by microvascular
injury, excessive extracellular matrix deposition, and
fibrosis of the connective tissues of the skin, lungs,
kidneys, heart, and gastrointestinal tract. The etiology of
SSc remains uncertain. Increasing evidence suggests that
there are many potential environmental triggers for SSc
and that host factors determine the susceptibility to disease
in response to these triggers. Bacterial and viral infectious
agents have been suspected to be contributing factors
in the development and progression of the pathologic
features of SSc (3).
The potential role of infectious agents in SSc has been
poorly investigated. The aim of the present study was to
evaluate the possible association between infection and
the etiology of the SSc.
* Correspondence: hubilgin@hotmail.com
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2. Materials and methods
2.1. Groups of patients
Thirty SSc patients who were admitted to the rheumatology
unit of the Konya Training and Research Hospital between
April 2009 and March 2012 and 30 sex- and age-matched
healthy controls were included in the study. All patients
with SSc met the American Rheumatism Association
criteria for diagnosis (4). The study group was classified
according to the extent of skin involvement (diffuse vs.
limited). The participants in this study had not received a
transfusion of blood or blood products.
2.2. ELISA assays
The presence of 9 different antibodies was examined in
sera samples from the 60 participants using an enzymelinked immunosorbent assay (ELISA) method. The sera
were tested against antibodies that reflect the existence
of current and past infections of Helicobacter pylori,
cytomegalovirus (CMV), Epstein–Barr virus (EBV), and
parvovirus B19.
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The following agents were used for the detection of
antibodies: anti-CMV (IgM and IgG) (EUROIMMUN
Medizinische Labordiagnostika AG, Lübeck, Germany),
EBV EBNA-1 (IgM) (IBL International GmbH, Hamburg
Germany), EBV EBNA-1 (IgG) (EUROIMMUN
Medizinische Labordiagnostika AG), EBV-CA (IgM)
(EUROIMMUN Medizinische Labordiagnostika AG),
anti-H. pylori (IgM and IgG) (EUROIMMUN Medizinische
Labordiagnostika AG), and antiparvovirus B19 (IgM and
IgG) (EUROIMMUN Medizinische Labordiagnostika
AG). All tests were evaluated by using a microplate reader
(Biotek ELx 800, BioTek Instruments, Inc., Winooski, VT,
USA). Interference from rheumatoid factor was avoided
by the addition of sheep IgG to the sample dilution buffer.
The participants underwent comprehensive examinations
and laboratory evaluations, including full blood count,
erythrocyte sedimentation rate, and renal and liver
functions.
A power analysis was conducted after recruitment.
Using an α level of 0.05, β level of 0.20, and sample size of
30, power was found as 70.7% for the study. Therefore, the
sample size of n = 30 may be sufficient. SSc is a rare disease
with an incidence rate of 2.3–10 per million (5). Hence,
the maximum amount of patients had been detected to be
included in the study.
2.2.1. ELISA measurements
Patient samples were diluted 1:101 with a sample buffer (10
µL of serum in 1.0 mL of sample buffer), and photometric
measurements were made at wavelengths of 450 nm and
630 nm for all the tests that were included in the study.
2.2.2. Anti-CMV IgM assay
The measurement unit was a ratio (extinction of the control
or patient samples/extinction of calibrator 2). Results
were evaluated as follows: <0.80 ratio was negative, ≥0.80
to <1.1 ratio was borderline, and ≥1.1 ratio was positive.
The detection limit of the test was a 0.05 ratio, intraassay
coefficients of variation (CVs) were 6.1%–11.3%, and
interassay CVs were 6.2%–9.3%. Specificity and sensitivity
rates of the test were 100% and 98.4%, respectively.
2.2.3. Anti-CMV IgG assay
The measurement unit was relative unit per milliliter (RU/
mL). Results were evaluated as follows: <16 RU/mL was
negative, ≥16 to <22 RU/mL was borderline, and ≥22 RU/
mL was positive. Linearity of the test was 2–200 RU/mL,
the detection limit of the test was 0.04 RU/mL, intraassay
CVs were 4.2%–5.4%, and interassay CVs were 5.7%–
11.2%. Specificity and sensitivity rates of the test were
100% and 98.4%, respectively.
2.2.4. EBV EBNA-1 IgM assay
The measurement unit was the cut-off index (COI). Results
were evaluated as follows: <0.8 COI was negative, 0.8–1.2
COI was equivocal, and >1.2 COI was positive. Intraassay

CV was 7.8%, and interassay CV was 12.1%. Specificity
and sensitivity rates of the test were >95% for each.
2.2.5. EBV EBNA-1 IgG assay
The measurement unit was RU/mL. Results were evaluated
as follows: <16 RU/mL was negative, ≥16 to <22 RU/mL
was borderline, and ≥22 RU/mL was positive. The linearity
of the test was 12–126 RU/mL, the detection limit of the
test was 0.9 RU/mL, intraassay CVs were 4.8%–8.9%,
and interassay CVs were 8.4%–10.9%. Specificity and
sensitivity rates of the test were 100% for each.
2.2.6. EBV CA IgM assay
The measurement unit was a ratio (extinction of the
control or patient samples/extinction of calibrator 2).
Results were evaluated as follows: <0.80 ratio was negative,
≥0.80 to <1.1 ratio was borderline, and ≥1.1 ratio was
positive. The detection limit of the test was a 0.01 ratio,
intraassay CVs were 3.3%–5.8%, and interassay CVs were
5.5%–6.9%. Specificity and sensitivity rates of the test were
100% for each.
2.2.7. EBV CA IgG assay
The measurement unit was RU/mL. Results were evaluated
as follows: <16 RU/mL was negative, ≥16 to <22 RU/mL
was borderline, and ≥22 RU/mL was positive. The linearity
of the test was 2–200 RU/mL, the detection limit of the
test was 1 RU/mL, intraassay CVs were 4.2%–7.4%, and
interassay CVs were 3.2%–8.2%. Specificity and sensitivity
rates of the test were 100% for each.
2.2.8. Anti-H. pylori IgM assay
The measurement unit was the COI. Results were
evaluated as follows: <0.8 COI was negative, 0.8–1.2 COI
was equivocal, and >1.2 COI was positive. Intraassay CV
was 8.1%, and interassay CV was 11.3%. Specificity and
sensitivity rates of the test were >95% for each.
2.2.9. Anti-H. pylori IgG assay
The measurement unit was RU/mL. Results were evaluated
as follows: <16 RU/mL was negative, ≥16 to <22 RU/mL
was borderline, and ≥22 RU/mL was positive. Detection
limit of the test was 0.7 RU/mL, intraassay CVs were 3.1%–
3.2%, and interassay CVs were 3.4%–4.6%. Specificity and
sensitivity rates of the test were 100% for each.
2.2.10. Antiparvovirus B19 IgM assay
The measurement unit was a ratio (extinction of the control
or patient samples/extinction of calibrator 2). Results were
evaluated as follows: <0.80 ratio was negative, ≥0.80 to
<1.1 ratio was borderline, and ≥1.1 ratio was positive. The
detection limit of the test was a 0.1 ratio, intraassay CVs
were 5.2%–6.0%, and interassay CVs were 5.6%–7.7%.
Specificity and sensitivity rates of the test were 97.9% and
100%, respectively.
2.2.11. Antiparvovirus B19 IgG assay
The measurement unit was international units (IU/mL).
Results were evaluated as follows: <4 IU/mL was negative,
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≥4 to <5.5 IU/mL was borderline, and ≥5.5 IU/mL was
positive. The linearity of the test was 1–100 IU/mL. The
detection limit of the test was 0.1 IU/mL, intraassay CVs
were 2.5%–7.7%, and interassay CVs were 1.6%–6.0%.
Specificity and sensitivity rates of the test were 100% for
each.
2.3. Ethical approval
Ethical approval was provided by the Ethics Committee
of Meram Medical School, Selçuk University (Konya,
Turkey) (ref: 2011/259). The patients provided both verbal
and written consent prior to their participation.
2.4. Statistical analysis
The results of tests were expressed as the number of
observations (n), mean ± standard deviation, median, and
min–max values. The results of the homogeneity (Levene
test) and normality tests (Shapiro–Wilk) were used to decide
which statistical methods to apply in the comparison of
the study groups. Normally distributed groups and groups
with homogeneous variances were compared using the
Student t-test. According to those tests results, parametric
test assumptions were not available for some variables, so
the comparisons of 2 independent groups were performed
by Mann–Whitney U test. Categorical data was analyzed
with the Fischer exact test and chi-square test. P < 0.05 was
considered statistically significant. All statistical analyses
were performed with SPSS 16.0 (SPSS Inc., Chicago, IL,
USA).
3. Results
The mean age of the subjects was 35 ± 15.25 years (19
females and 11 males, age range 7–60) for the SSc patients
and 37 ± 16.35 years (18 females and 12 males, age range
8–59) for the control group. Table 1 summarizes the
demographic characteristics of the study population.
In our population, 73.3% of SSc patients had H. pylori
antibodies (IgM and/or IgG), compared with 46.6%
of the control group (P < 0.05). Anti-CMV antibodies
(IgM and/or IgG) were detected in 93.3% of SSc patients,
compared with 73.3% of the control group (P < 0.05). EBV
antibodies (IgM and/or IgG) were detected in 93.3% of SSc

patients, compared with 66.6% of the control group (P <
0.05). Parvovirus B19 antibodies (IgM and/or IgG) were
detected in 86.6% of SSc patients, compared with 63.3% of
the control group (P < 0.05). Table 2 shows the prevalence
of antibodies against these infections in patients with SSc
and patients in the control group.
There was no statistically significant difference between
the limited SSc and diffuse SSc patients for H. pylori,
CMV, EBV and parvovirus B19 infections. The prevalence
of recent infections (IgM-positive but IgG-negative) was
similar between the SSc patients and controls.
4. Discussion
Infections can trigger autoimmune diseases. This fact
is well established in the literature. SSc is among the
less investigated autoimmune diseases, and not much
information exists on the disease pathogenesis and triggers
(6–8). In the current study, we investigated the relationship
between past and recent infections and the etiology of SSc.
Many agents have been postulated as being involved
in the cause of the disease. Bacterial and viral infectious
agents have been suspected to be contributing factors in
the development and progression of SSc. The rationale for
this infection hypothesis is that many SSc-like symptoms
are transiently elicited by infectious agents in otherwise
healthy individuals. Some researchers have suggested that
the production of specific autoantibodies in SSc patients
is the result of an antigen-driven response caused by
molecular mimicry. Molecular mimicry is a mechanism of
autoimmune disease that may explain the pathogenicity of
antibodies against viral proteins in SSc patients (9). Selfreactive antibodies against a virus may induce endothelial
cell apoptosis through the interaction with the integrin
α3β1 and α6β1 NAG-proteins complex (9). Endothelial
injury represents one of the first steps in the pathogenesis
of SSc. Endothelial cells may be infected by bacteria or
viruses that may be instrumental in inducing vasculitis
(10).
Attempts to establish a link between the H. pylori
infection status and SSc have yielded conflicting results.
One study identified higher incidence rates of H. pylori

Table 1. Demographic characteristics of the study population.

Characteristics

SSc

Controls

P-value Limited+diffuse SSc vs.
controls

Limited

Diffuse

Limited+diffuse

No. of patients

18

12

30

30

Female/male

1.57

2

1.72

1.5

P = 0.792

Mean age, years

34 ± 16.25

36 ± 13.45

35 ± 15.25

37 ± 16.35

P = 0.529

Disease duration, years

2.7

3.1

2.9

-
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Table 2. Prevalence of antibodies against infections in patients with systemic sclerosis and control groups.
SSc (30)
Limited (18) Diffuse (12) Limited+diffuse (30)

Controls (30)

P-value
Limited+diffuse SSc vs. controls

Prevalence of H. pylori antibodies, % of patients
IgM+, IgG-

5.5

8.3

6.6

3.3

P = 1.0

IgM+, IgG+

16.6

16.6

16.6

10

P = 0.706

IgM-, IgG+

50

50

50

33.3

P = 0.190

IgM+ and/or IgG+

72.2

75

73.3

46.6

P = 0.035

Prevalence of CMV antibodies, % of patients
IgM+, IgG-

0

0

0

3.3

P = 1.0

IgM+, IgG+

22.2

16.6

20

13.3

P = 0.731

IgM-, IgG+

72.2

83.3

76.6

56.6

P = 0.100

IgM+ and/or IgG+

94.4

91.6

93.3

73.3

P = 0.038

Prevalence of EBV antibodies, % of patients
IgM+, IgG-

5.5

8.3

6.6

6.6

P = 1.0

IgM+, IgG+

11.1

16.6

13.3

6.6

P = 0.671

IgM-, IgG+

72.2

83.3

76.6

56.6

P = 0.100

IgM+ and/or IgG+

94.4

91.6

93.3

66.6

P = 0.010

Prevalence of parvovirus B19 antibodies, % of patients
IgM+, IgG-

5.5

0

3.3

0

P = 1.0

IgM+, IgG+

5.5

8.3

6.6

3.3

P = 1.0

IgM-, IgG+

72.2

75

73.3

60

P = 0.273

IgM+ and/or IgG+

88.8

83.3

86.6

63.3

P = 0.037

infection in patients with rheumatic diseases, including
SSc, as detected by serologic analysis (11). In contrast, 2
larger studies discovered there was no difference in the
H. pylori infection rates between patients with SSc with
Raynaud phenomenon and healthy controls (12,13). A
recent study (14) indicated that, although there is no
difference in the H. pylori infection rate between control
subjects and patients with SSc, 90% of patients with SSc
were infected with the virulent CagA strain compared
with 37% of infected control subjects. In a study of patients
with primary Raynaud phenomenon, the eradication
of H. pylori infections was associated with the complete
disappearance of the episodes of Raynaud phenomenon in
17% of treated patients and a reduction in symptoms in an
additional 72% (15). In the present study the prevalence of
H. pylori antibodies (both IgM and IgG) was significantly
higher among SSc patients than in controls.

CMV may play a role in SSc pathogenesis due to its ability
to infect both endothelial and monocyte/macrophage cells,
and through the upregulation of fibrogenic cytokines and
the induction of immune dysregulation (16,17). CMV, as a
possible trigger for SSc, has been suggested by the reported
appearance of SSc shortly after acute episodes of viral
infections (18). The most direct evidence of a link between
CMV and SSc is the presence of high-titer IgG antibodies
against the polyglycine motifs of CMV (19). In addition,
antitopoisomerase I (Scl-70) autoantibodies, which are
characteristic of diffuse SSc, can cross-react with a peptide
sequence of the UL70 protein of CMV (20). One difficulty
in establishing a clear association between CMV and SSc
is the fact that 60% to 90% of adults display serologic
evidence of past CMV infection, yet SSc affects at most
3 in 10,000 people. We discovered that the prevalence of
anti-CMV antibodies (both IgM and IgG) is higher among
SSc patients than in controls.
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EBV DNA has been detected in the lungs of SSc patients
(21). It has been observed that an antibody against hnRNP
autoantigen called p542 may develop in mononucleosis,
and IgG anti-p542 has been discovered in SSc (22). In
these patients, autoantibodies against a 60–62-kDa cellular
protein, which cross-reacts with the glycine/alanine repeat
in EBNA-1, may have been detected (19). Farina et al. (23)
showed that SSc fibroblasts have greatly diminished IFNinducible gene response upon TLR7/9 agonist stimulation.
This is possibly one of the reasons why EBV is able to
infect and persist in SSc fibroblasts. They suggested that
EBV infection could contribute to fibrosis in SSc skin. In
the current study, the prevalence of EBV antibodies (both
IgM and IgG) was significantly higher among SSc patients
than in controls.
Parvovirus B19 has been proposed as a causative
agent in rheumatoid disease and other vascular injury
syndromes, including Wegener granulomatosis (24),
microscopic polyarteritis nodosa (25), Henoch–Schönlein
purpura (26), and dermatomyositis (27) in SSc. A direct
correlation between the extent of degenerative endothelial
cell alterations and the degree of B19RNA expression
suggested a causal role of B19 in the propagation of
endothelial cell dysfunction (28). A possible role for
parvovirus B19 infection in the evolution of SSc is
suggested by the presence of B19 at a high percentage (57%)
in bone marrow biopsies from unselected SSc patients in

the absence of B19 viremia (29). It has been suggested
that bone marrow may represent a reservoir from which
the B19 virus could spread to SSc target tissues (30). We
detected a significantly higher prevalence of parvovirus
B19 antibodies (both IgM and IgG) in SSc patients than
in controls.
We discovered a higher prevalence of infectious agents
in SSc patients than in healthy controls. SSc likely occurs
as a result of interactions between the infectious agent and
a cascade of host-specific factors and events. This is not
surprising, because the immune response to infection is
highly individual. It is controlled by multiple genes, age,
and the route of infection. In a disease as varied, complex,
and rare as SSc, infection prevalence alone should not
be expected to provide sufficient evidence for or against
a pathological role in the disease. Therefore, additional
factors such as coinfections, differences in the strains of
infectious agents, and immunological and genetic host
factors will have to be further identified and controlled to
understand the role of infectious agents in SSc.
Our study had several limitations. First, the relationship
between exposure time to the viral infections and clinical
onset of the disease was not determined. Second, the study
group was small owing to the rarity of the disorder. This
condition is estimated to occur in 2.3–10 people per 1
million (5). Third, the impact of environmental factors in
the onset of SSc was not analyzed.
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